Maxidex (Dexamethasone)

Maxidex (dexamethasone ophthalmic suspension) is used to manage inflammatory eye conditions by reducing ocular inflammation.

• Post‑operative ocular inflammation: reduces swelling, pain and redness after eye surgery.
• Anterior uveitis: controls intra‑ocular inflammation and helps prevent vision‑threatening complications.
• Ocular allergic reactions: alleviates redness, itching and edema caused by allergens.
• Iridocyclitis: suppresses inflammation of the iris and ciliary body, improving comfort and visual clarity.

• Dexamethasone binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This action inhibits phospholipase A2 and reduces the synthesis of prostaglandins and leukotrienes, while also decreasing cytokine production. The combined effect dampens inflammatory cell migration and vascular permeability in ocular tissues, providing potent anti‑inflammatory activity.

Common Side Effects

• Eye irritation or burning sensation after instillation.
• Transient blurred vision.
• Increased intra‑ocular pressure in susceptible individuals.
• Mild cataract formation with prolonged use.

Serious or Rare Side Effects

• Secondary ocular infection (bacterial or fungal).
• Severe allergic reaction such as angio‑edema.
• Steroid‑induced glaucoma leading to optic nerve damage.
• Corneal ulceration or perforation.

Before using Maxidex, consider the following precautions:

• Monitor intra‑ocular pressure: patients at risk for steroid‑induced glaucoma should have regular pressure checks.
• Assess for active ocular infection: avoid use if a bacterial, viral or fungal eye infection is present.
• Use with caution in diabetic patients: corticosteroids may affect blood glucose control.
• Avoid in patients with known hypersensitivity to dexamethasone or any formulation component.
• Store at room temperature: keep in the original container, protect from light and moisture.

Maxidex may interact with other ophthalmic or systemic agents.

Major Interactions (Avoid)

• Systemic corticosteroids: additive immunosuppressive effect may increase infection risk.
• Antifungal eye drops (e.g., natamycin): may reduce the efficacy of dexamethasone.
• CYP3A4 inhibitors (e.g., ketoconazole): can increase systemic exposure if absorbed.

Moderate Interactions (Monitor Closely)

• Beta‑blocker eye drops: may mask steroid‑induced ocular hypertension.
• Anticholinergic eye drops: could affect pupil dynamics when combined.
• Systemic CYP3A4 inducers (e.g., rifampicin): may lower dexamethasone levels, reducing anti‑inflammatory effect.